NEWSMAX @NEWSMAX
The U.S. National Institutes of Health's $1 billion RECOVER Initiative has picked Pfizer Inc's antiviral drug Paxlovid as the first treatment it will study in patients with long COVID, organizers of the study said on Thursday.https://t.co/b8ooyqXx9M — PolitiTweet.org